ARCHIVES

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

This article is from The Cancer Letter archive.

Vol. 26 No. 13 | March 31, 2000

Download PDF Visit The Full Archive

Related Articles

NIH Emerges From Republican Revolution With Another Increase in Appropriations

October 4, 1996

DCT Board Sends Letter Opposing Bill Requiring Research On RU 486

November 13, 1992

Avastin-Zybrestat Combination Increases Progression-Free Survival in Phase II Trial

March 28, 2014

The NLST at a Glance

August 2, 2013

FDA Clears Avastin-Interferon Combination In Renal Cancer; Interferon Role Undefined.

August 7, 2009

FDA Committee Can’t Find “Reasonable” Evidence Alkylating Agent Clinical Use Is Carcinogenic

September 10, 1976